Country: Ireland
Language: English
Source: HPRA (Health Products Regulatory Authority)
5-AMINOLEVULINIC ACID HYDROCHLORIDE
Spirig Pharma Europe GmbH
8 Milligram
Medicated Plaster
2012-02-24
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Alacare 8 mg medicated plaster 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each medicated plaster of 4 cm² contains 8 mg 5-aminolevulinic acid, 2 mg per cm 2 . For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Medicated plaster. Each plaster has a size of 4 cm², is square with rounded corners and consists of a skin tone backing foil and a self- adhesive matrix, covered by a release liner which is removed prior to use. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Single use treatment of mild actinic keratoses lesions with a maximum diameter of 1.8 cm on the face and scalp (hairless areas). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Adults (including the elderly) For the treatment of AK with one session photodynamic therapy (PDT), apply up to a maximum of six Alacare patches used on six different lesions to the patient on a single treatment session. If the Alacare plaster does not stick to the lesions properly, it can be fixed with an adhesive strip. After four hours, remove the Alacare plaster(s) and expose the lesion(s) to red light with a narrow band red light source with a spectrum of 630 ± 3 nm and a total light dose of 37 J/cm² at the lesion surface. Only CE marked lamps should be used, equipped with necessary filters and/or reflecting mirrors to minimize exposure to heat, blue light and UV radiation. It is important to ensure that the correct light dose is administered. The light dose is determined by factors such as the size of the light field, the distance between lamp and skin surface and illumination time. These factors vary with lamp type, and the lamp should be used according to the user manual. Patient and operator should adhere to safety Read the complete document